This technology involves a collection of patient-derived breast cancer models developed from freshly isolated tumor tissues obtained within 60 minutes post-surgery. It features a robust culturing protocol that preserves the histological, genomic, and transcriptomic profiles of the original tumors. The models display diverse growth morphologies and maintain key markers, such as the estrogen receptor, making them compatible with various manipulations, including transient siRNA transfection and lentiviral-mediated reporter expression. Additionally, certain cultures can be transitioned to suspension conditions, broadening the scope of experimental assays, while single-cell RNA sequencing confirms the retention of epithelial heterogeneity.
Description
This approach is differentiated by its rapid tissue procurement process and meticulous adherence to protocols that capture the intrinsic complexity of breast cancer. Unlike traditional cell lines, these models retain dynamic and diverse cellular characteristics, offering a more accurate representation of tumor biology. Their adaptability to a range of genetic modifications and assay formats further enhances their value, presenting a unique resource for preclinical studies, drug discovery, and personalized medicine research.
Applications
- Preclinical drug screening
- Precision medicine testing
- Biomarker discovery research
- Therapeutic efficacy evaluation
- Personalized oncology models
Advantages
- Faithfully replicates the histological, genomic, and transcriptomic profiles of the original tumor, preserving patient-specific heterogeneity.
- Enables versatile genetic manipulation with methods such as siRNA transfection and lentiviral-mediated reporter expression.
- Supports diverse culture conditions, including both 3D matrix and suspension formats, allowing for a broad range of assay types.
- Provides a robust preclinical model that offers enhanced phenotypic fidelity compared to conventional breast cancer cell lines.
- Facilitates personalized research and drug discovery by accurately modeling different breast cancer subtypes and treatment responses.
IP Status
Research Tool
